Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.12 | N/A | +37.82% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.12 | N/A | +37.82% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions affecting growth. They reiterated their commitment to advancing their pipeline.
Management highlighted ongoing challenges in the market.
They emphasized the need for continued focus on product development.
BioCryst Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock dropped 6.7% likely due to the lack of revenue details and no updated guidance. The market may be reacting to uncertainties surrounding future performance and management's cautious tone.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
Nov 3, 2014